AEON Biopharma Inc. (AEON)
AEON trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | AEON on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001837607 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "As a result of these conditions, management has concluded that there is substantial doubt about the Company's ability to continue as a going concern and to meet its obligations as they become due within one year after the date that these condensed consolidated financial statements are issued." | 10-Q 2026-08-12 |
| Cash and burn | $3.4M cash; operating cash flow -$3.4M a quarter. | Report 2026-06-30 |
| Shares outstanding | 49,882,790 (2026-08-06); 1,164,378 a year earlier; 37,159,600 three years earlier. 3y figure adjusted for split (1-for-72 overall). | Cover page 2026-08-06 |
| Reverse splits, 3 years | 1; latest 1-for-72 on 2025-02-26 | Source 2025-02-26 |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-02-09 |
| Exchange deficiency notices, 12 months | 1 (8-K item 3.01) | 8-K 2026-04-03 |
| Auditor | KPMG LLP, San Diego, California, United States | PCAOB Form AP 2026-04-22 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $242K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$1.2M | -$3.7M | $3.4M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2026 2026-03-31 | Not filed | -$11.8M | -$2.6M | $6.2M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | Not filed | -$37.1M | -$4.7M | $3.0M | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2025 2025-09-30 | Not filed | -$4.5M | -$2.6M | $5.9M | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | Not filed | -$6.6M | -$2.1M | $8.4M | No debt tags | Needs four quarters | 10-Q 2026-08-12 |
| Q1 2025 2025-03-31 | Not filed | $9.1M | -$7.9M | $10.4M | No debt tags | Needs four quarters | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | Not filed | $2.1M | -$621K | $13K | No debt tags | Needs four quarters | 10-K 2026-03-30 |
| Q3 2024 2024-09-30 | Not filed | -$6.2M | -$3.0M | $537K | No debt tags | Needs four quarters | 10-Q 2025-11-14 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-11-03 |
| Latest annual report | 10-K | 2026-03-30 |
| Latest quarterly / interim | 10-Q | 2026-08-12 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEF 14A | 2026-10-26 |
Source: SEC EDGAR submissions feed, 365 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -13.1% |
| 1 month | -33.5% |
| 3 months | -43.5% |
| Year to date | -86.1% |
| 1 year | -83.7% |
| From 52-week high | -88.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CLRB | Cellectar Biosciences Inc. | $1.01 | -11.40% | $10.1M |
| BFRI | Biofrontera Inc. | $0.5700 | -18.58% | $10.2M |
| HIND | Vyome Holdings Inc. | $1.53 | -3.16% | $10.7M |
| LEXX | Lexaria Bioscience Corp. | $4.41 | -0.68% | $9.3M |
| PTN | Palatin Technologies Inc. | $6.13 | -1.69% | $10.9M |
| GDTC | CytoMed Therapeutics Limited | $0.7739 | -6.68% | $9.2M |
| RADX | Radiopharm Theranostics Limited | $0.7676 | +1.00% | $11.1M |
| BFRG | Bullfrog AI Holdings Inc. | $0.4878 | -9.92% | $9.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier